A Preclinical Evaluation of Minnelide as a Therapeutic Agent Against Pancreatic Cancer
- 17 October 2012
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 4 (156), 156ra139
- https://doi.org/10.1126/scitranslmed.3004334
Abstract
Pancreatic cancer is one of the most lethal human malignancies with an all-stage 5-year survival frequency of G12D; Trp53R172H; Pdx-1Cre). In these multiple complementary models of pancreatic cancer, Minnelide was highly effective in reducing pancreatic tumor growth and spread, and improving survival. Together, our results suggest that Minnelide shows promise as a potent chemotherapeutic agent against pancreatic cancer, and support the evaluation of Minnelide in clinical trials against this deadly disease.Keywords
This publication has 36 references indexed in Scilit:
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal AdenocarcinomaCancer Cell, 2012
- Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancerCancer Science, 2011
- Triptolide and TRAIL Combination Enhances Apoptosis in CholangiocarcinomaJournal of Surgical Research, 2010
- Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic CancerMolecular Cancer Therapeutics, 2010
- Pancreatic CancerThe New England Journal of Medicine, 2010
- Smac Mimetic Increases Chemotherapy Response and Improves Survival in Mice with Pancreatic CancerCancer Research, 2010
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic CancerScience, 2009
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic AnalysesScience, 2008
- Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancerBMC Cancer, 2007
- Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracilEuropean Journal of Cancer, 1997